Published trial averages: Semaglutide: ~1015% of body weight Tirzepatide: ~1522% of body weight A typical arc: minimal change during early titration, a steadier phase over the following months, then a maintenance phase
Patients should contact their GP if they experience concerning symptoms and report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
At the same time, use of liraglutide, the previously dominant medication in the class sold as Victoza and Saxenda, fell sharply in both groups
The Importance of Preliminary Testing Before starting any glutathione regimen, it's crucial to understand your current levels clearly
Storage: Store in a cool, dry, and well-ventilated place
Community forums remain an invaluable resource for current updates and managing expectations